Drug metabolism and personalized therapy最新文献

{"title":"Impact of environmental toxicants exposure on gut-brain axis in Parkinson disease.","authors":"Taiwo G Olubodun-Obadun,&nbsp;Ismail O Ishola,&nbsp;Olufunmilayo O Adeyemi","doi":"10.1515/dmpt-2021-0144","DOIUrl":"https://doi.org/10.1515/dmpt-2021-0144","url":null,"abstract":"<p><p>Parkinson disease (PD) is a major public health challenge as many of the current drugs used in its management provide symptomatic relieve without preventing the underlying cause of the neurodegeneration. Similarly, the non-motor complications of PD, especially the gastrointestinal tract (GIT) disturbance increases the disease burden on both the PD patient and caregivers. Different theories have been postulated regarding the mechanisms or pathways involved in PD pathology but gut-brain axis involvement has gained much more momentum. This pathway was first suggested by Braak and colleagues in 2003, where they suggested that PD starts from the GIT before spreading to the brain. However, human exposure to environmental toxicants known to inhibit mitochondrial complex I activity such as rotenone, paraquat and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) are well associated with PD. Several reports have shown that oral exposure of laboratory animals to rotenone causes mitochondria dysfunction, GIT disturbance, overexpression of alpha synuclein and microbiota imbalance. This review focuses on the mechanism(s) through which rotenone induces PD pathogenesis and potential for therapeutic small molecules targeting these processes at the earliest stages of the disease. We also focused on the interaction between the GI microbiota and PD pathology.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"37 4","pages":"329-336"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10364378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential factors of <i>Helicobacter pylori</i> resistance to clarithromycin.","authors":"Svetlana Serebrova,&nbsp;Daria Kurguzova,&nbsp;Lyudmila Krasnykh,&nbsp;Galina Vasilenko,&nbsp;Vladimir Drozdov,&nbsp;Natalia Lazareva,&nbsp;Eugenia Shikh,&nbsp;Marina Zhuravleva,&nbsp;Svetlana Rykova,&nbsp;Natalia Eremenko,&nbsp;Elena Kareva,&nbsp;Karin Mirzaev,&nbsp;Dmitriy Sychev,&nbsp;Alexey Prokofiev","doi":"10.1515/dmpt-2021-0193","DOIUrl":"https://doi.org/10.1515/dmpt-2021-0193","url":null,"abstract":"<p><strong>Objectives: </strong>A comparative dissolution kinetics test (CDKT) and bioequivalence studies of generic proton pump inhibitors (PPIs) do not model pharmacological acid suppression (PAS) and pathological duodenogastric reflux (PDGR). This study aimed to model them in CDKT to assess drugs stability and potential pantoprazole-clarithromycin interactions.</p><p><strong>Methods: </strong>In CDKT, PDGR (dissolution medium pH 7.00 ± 0.05, preexposure at pH 1.20 ± 0.05) and PAS (pH 4.00 ± 0.05) were modelled for original pantoprazole (OP) and its generics (GP1-4). In CDKT with high-performance liquid chromatography, dissolution gastric medium in adequate (pH 4.00 ± 0.05) and inadequate (pH 1.20 ± 0.05) PAS were modelled for original clarithromycin (OC) and its generics (GC1-4).</p><p><strong>Results: </strong>After exposure in pH 7.00 ± 0.05, pantoprazole was released from GP1 within 10 min in the amount of 68.8%. In рН 4.00 ± 0.05, 83.0% and 81.5% of pantoprazole were released from GP1 and GP4. When OP, GP2 and GP3 were placed in pH 7.00 ± 0.05, pantoprazole was released in amount: 99.4%, 88.0% and 98.2%. Clarithromycin releasing from OC, GC1, GC2, GC3, GC4 in pH 4.00 ± 0.05 was 93.5%, 91.6%, 92.9%, 79.4% and 83.0%. In pH 1.20 ± 0.05: 9.7%, 6.7%, 8.5%, 33.3%, 28.8%.</p><p><strong>Conclusions: </strong>Destruction of enteric coats of some local pantoprazole generics in CDKT-models might be a potential factor for inadequate therapy.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"37 4","pages":"383-391"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10714296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of <i>CYP2C9</i>, <i>PTGS-1</i> and <i>PTGS-2</i> gene polymorphisms on the efficiency and safety of postoperative analgesia with ketoprofen.","authors":"Dmitry A Sychev,&nbsp;Tatiana E Morozova,&nbsp;Dmitry A Shatskiy,&nbsp;Nadezhda V Shikh,&nbsp;Evgeniya V Shikh,&nbsp;Tatiana B Andrushchyshina,&nbsp;Maria V Lukina,&nbsp;Anastasia A Kachanova,&nbsp;Zhannet A Sozaeva,&nbsp;Sherzod P Abdullaev,&nbsp;Natalia P Denisenko,&nbsp;Kristina A Ryzhikova","doi":"10.1515/dmpt-2021-0222","DOIUrl":"https://doi.org/10.1515/dmpt-2021-0222","url":null,"abstract":"<p><strong>Objectives: </strong>Patients undergoing cardiac surgery develop post-sternotomy pain syndrome. The aim of this study was evaluation of the influence of <i>CYP2C9</i>, <i>PTGS-1</i> and <i>PTGS-2</i> genes polymorphisms on the efficacy and safety of postoperative analgesia with ketoprofen in patients with coronary artery disease after cardiac surgery.</p><p><strong>Methods: </strong>The study included 90 patients undergoing cardiac surgery. A real-time polymerase chain reaction was used for the detection of single nucleotide polymorphisms (SNP). Pain intensity was measured by the Numeric Rating Scale (NRS). Dyspeptic symptoms were evaluated using the Gastrointestinal Symptom Rating Scale (GSRS). Acute kidney injury (AKI) was determined by Kidney Disease Improving Global Outcomes criteria.</p><p><strong>Results: </strong>Pain intensity by the NRS score was significantly higher in patients with <i>CYP2C9*3 АA</i> genotype compared to <i>АC</i> genotype: 7 [1,10] and 6 [2,7] (p=0.003); 7 [1,10] and 6 [2,7] (p=0.04); 6 [0; 10] and 5 [2,6] (p=0.04); 5 [0; 8] and 3 [0; 8] (p=0.02), on days 1, 2, 3 and 5 in the postoperative period, respectively. GSRS score was higher in patients with <i>CYP2C9*2 CT</i> genotype compared to <i>CС</i> genotype: 19 [15; 42] and 18 [15,36] (p=0.04), respectively. There were no significant differences in the pain intensity, dyspepsia severity and AKI frequency in patients with homozygous and heterozygous genotypes for <i>PTGS-1</i> rs10306135, <i>PTGS-1</i> rs12353214, <i>PTGS-2</i> rs20417.</p><p><strong>Conclusions: </strong><i>CYP2C9*3</i> and <i>CYP2C9*2</i> gene polymorphisms may affect efficacy and safety of postoperative analgesia with ketoprofen in patients with coronary artery disease after cardiac surgery.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"37 4","pages":"361-368"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10355592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of <i>VKORC1</i> and <i>CYP2C9</i> single-nucleotide polymorphisms with warfarin dose adjustment in Saudi patients.","authors":"Jasmine Holail,&nbsp;Reem Mobarak,&nbsp;Bandar Al-Ghamdi,&nbsp;Ahmad Aljada,&nbsp;Hana Fakhoury","doi":"10.1515/dmpt-2022-0108","DOIUrl":"https://doi.org/10.1515/dmpt-2022-0108","url":null,"abstract":"<p><strong>Objectives: </strong>Despite its wide usage, warfarin therapy remains challenging due to its narrow therapeutic index, inter-individual response variability, and risk of bleeding. Previous reports have suggested that polymorphisms in <i>VKORC1</i> and <i>CYP2C9</i> genes could influence warfarin therapy. Herein, we investigated whether <i>VKORC1</i> -1173C>T, <i>CYP2C9*2</i>, and <i>CYP2C9*3</i> gene polymorphisms are associated with warfarin dose adjustment and related bleeding events.</p><p><strong>Methods: </strong>This cross-sectional study was conducted on Saudi adults receiving warfarin for more than 1 month. Their demographics and relevant clinical data were obtained. Genotyping for <i>VKORC1</i> -1173C>T, <i>CYP2C9*2</i>, and <i>CYP2C9*2</i> genotypes was performed.</p><p><strong>Results: </strong>Patients who are homozygous for the mutant T allele <i>VKORC1</i> T/T required the lowest warfarin daily maintenance dose, compared to <i>VKORC1</i> C/T and <i>VKORC1</i> C/C. Similarly, there was a significant reduction in warfarin daily maintenance dose among <i>CYP2C9*1/*3</i> and <i>CYP2C9*1/*2</i> groups compared to <i>CYP2C9*1/*1</i>. However, we found no significant correlation between the studied polymorphisms and warfarin-associated bleeding.</p><p><strong>Conclusions: </strong>Similar to other populations, the <i>VKORC1</i> and <i>CYP2C9</i> gene polymorphisms are significantly associated with warfarin dosage in Saudi patients. The presence of at least one copy of the mutant alleles for <i>VKORC1</i> -1173C>T, <i>CYP2C9*2</i>, and <i>CYP2C9*3</i> is associated with a significant reduction in warfarin maintenance dose.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"37 4","pages":"353-359"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10732710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toxicological evaluation of hydroethanol leaf extract of <i>Pupalia lappacea</i> (Linn.) Juss. (Amaranthaceae) in rodents.","authors":"Murtala Akanji Abdullahi,&nbsp;Elijah Oladapo Oyinloye,&nbsp;Akinyinka Alabi,&nbsp;Aderonke Adeyinka Aderinola,&nbsp;Luqman Opeyemi Ogunjimi,&nbsp;Adesina A Omoloye,&nbsp;Ayobami A Odusote,&nbsp;Joseph O Olusola,&nbsp;Oluwatosin O Adebayo,&nbsp;Wasiu Eniola Olooto","doi":"10.1515/dmpt-2021-0115","DOIUrl":"https://doi.org/10.1515/dmpt-2021-0115","url":null,"abstract":"<p><strong>Objectives: </strong>Several studies have established the ethnobotanical benefits of <i>Pupalia lappacea</i> (PL) in laboratory animals without extensive toxicological evaluation of its safety profiles. Thus, an extensive toxicological investigation of sub-chronic oral administration of the hydroethanol leaf extract of <i>P. lappacea</i> in rodents was carried out in this study.</p><p><strong>Methods: </strong>Different groups of rats were treated orally with the extract (10, 50 and 250 mg/kg) daily for 90 consecutive days. The control group received distilled water (10 mL/kg). After 90 days, some rats were left for additional 30 days without treatment for reversibility study. Blood and organs samples were collected for different evaluations at the end of study periods.</p><p><strong>Results: </strong>The extract decreased the bodyweights, feeding and water intakes in female rats. PL increased the weights of the liver and kidney in male rats. PL increased the red blood cell (RBC), packed cell volume (PCV), hemoglobin (Hb), triglycerides (TRIG), cholesterol and high density lipoprotein (HDL) contents in rats. PL (250 mg/kg) significantly reduced the sperm motility and serum testosterone level. Cyto-architectural distortions of the testes, liver and spleen were visible.</p><p><strong>Conclusions: </strong>The findings showed that <i>P. lappacea</i> is relatively safe at lower doses but cautions should be taken at higher dose.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"37 2","pages":"201-217"},"PeriodicalIF":0.0,"publicationDate":"2022-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40268878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synergistic anti-cancer effects of Nigella sativa seed oil and conventional cytotoxic agent against human breast cancer","authors":"W. A. Baig, Kholoud Alwosaibai, K. M. Al-Jubran, T. Chaudhry, Nouf Al-Dowish, Fatimah A. Alsaffar, Md Anzar Alam","doi":"10.1515/dmpt-2021-0229","DOIUrl":"https://doi.org/10.1515/dmpt-2021-0229","url":null,"abstract":"Abstract Objectives Breast cancer is the most commonly diagnosed invasive non-skin malignancy in women worldwide, and it is the leading cause of cancer-related deaths in them. Nigella sativa Linn. seed oil has been found to be effective in cancer treatment as well as having anti-cancer properties in some other types of cancers. The study looked into the synergistic cytotoxic effects of N. sativa Linn. seed oil and doxorubicin in the treatment of human breast cancer cells (MCF-7). Methods Nigella sativa Linn. seed oil was used to evaluate its effect on human breast cancer cells, either alone or in conjunction with doxorubicin. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) tests were used to examine cell proliferation and cell viability, while phase-contrast inverted microscopy was used to examine cellular morphology. Furthermore, the role of N. sativa seed oil in decreasing cell tumorigenicity features was highlighted by testing the cancer cell migration using the wound healing assay. Results Results showed that higher concentrations (50 μg/mL) of N. sativa Linn. seed oil changed the breast cancer cell morphology and decreased the cell proliferation and viability. Breast cancer cells treated with black seed oil decreased cell movement after 24 hours compared to the untreated cell in the wound healing assay. Whereas, only the higher concentration of doxorubicin (0.5–2.5 μg/mL) reduced cell proliferation and cell viability. Moreover, the combination treatment of 50 μg/mL of black seed oil with different concentrations of doxorubicin caused a significant cell proliferation reduction and decreased cell viability. The activity was seen optimum at lower concentration (0.1 µg/mL) of doxorubicin. Conclusions There was decreased cell proliferation and cell viability when N. sativa seed oil was used alone or in conjunction with doxorubicin in Breast cancer cells (MCF-7) revealing potential opportunities in the field of cancer treatment.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"68 1","pages":"315 - 321"},"PeriodicalIF":0.0,"publicationDate":"2022-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82193975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MTHFR c.665C>T guided fluoropyrimidine therapy in cancer: gender-dependent effect on dose requirements","authors":"Charalampia Ioannou, G. Ragia, I. Balgkouranidou, N. Xenidis, K. Amarantidis, T. Koukaki, E. Biziota, S. Kakolyris, V. Manolopoulos","doi":"10.1515/dmpt-2021-0219","DOIUrl":"https://doi.org/10.1515/dmpt-2021-0219","url":null,"abstract":"Abstract Objectives The fluoropyrimidine derivatives 5-Fluorouracil and Capecitabine are widely used for the treatment of solid tumors. Fluoropyrimidine metabolism involves a cascade of different enzymes, including MTHFR enzyme. MTHFR c.665C>T polymorphism, leading to decreased MTHFR activity, is a potential pharmacogenomic marker for fluoropyrimidine drug response. The aim of the present study was to analyze the association of MTHFR c.665C>T polymorphism with fluoropyrimidine response in terms of therapy induced adverse events (AEs), requirement of dose reduction and delayed drug administration or therapy discontinuation. Methods The study group consisted of 313 fluoropyrimidine-treated cancer patients. PCR-RFLP was used to analyze MTHFR c.665C>T polymorphism. Results In female patients, MTHFR c.665 CT and TT genotypes were associated with dose reduction (p=0.029). In gender stratification, regression analysis adjusted for age of disease onset, body surface area and AE incidence, showed that MTHFR CT and TT genotypes increased both need for fluoropyrimidine dose reduction (OR 5.050, 95% CI 1.346–18.948, p=0.016) and percentage of dose reduction (β=3.318, 95% C.I. 1.056–5.580, p=0.004) in female patients. Such differences were not present in male patients. No other associations were found. Conclusions MTHFR c.665C>T polymorphism was associated with fluoropyrimidine dose reduction in female cancer patients. This gender*MTHFR interaction merits further investigation.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"41 1","pages":"323 - 327"},"PeriodicalIF":0.0,"publicationDate":"2022-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90252811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The markers of the organic acidemias and their ratios in healthy neonates in Serbian population","authors":"A. Beletić, Aleksandra Tijanić, P. Chrastina, T. Nikolić, A. Stefanović, S. Stanković","doi":"10.1515/dmpt-2021-0218","DOIUrl":"https://doi.org/10.1515/dmpt-2021-0218","url":null,"abstract":"Abstract Objectives The newborn screening (NBS) program in the Republic of Serbia has several decades of tradition, but it has not included any organic acidemias (OA). Therefore, this study aimed to establish the cut-offs of the corresponding NBS markers in the population of healthy newborns. Methods In dried blood samples (DBS) collected from 1,771 healthy newborns, we analyzed levels of propionylcarnitine (C3), isovalerylcarnitine (C5), and glutarylcarnitine (C5DC) using tandem mass spectrometry. Further we calculated the following ratios: C3/acetylcarnitine (C3/C2), C3/palmitoylcarnitine (C3/C16), C5/ free carnitine (C0), C5/C2, C5/C3, C5DC/octanoylcarnitine (C8), and C5DC/C0. Results The cut-offs for methylmalonic acidemia (MMA) or propionic acidemia (PA) were C3>5.73 μmol/L, C3/C2>0.23, and C3/C16>2.36. Based on the study findings, the screening results indicative for isovaleric acidemia (IVA) would include C5>0.372 μmol/L, C5/C0>0.020, C5/C2>0.019, and C5/C3>0.31. Finally, C5DC>0.303 μmol/L, C5DC/C8>7.1, and C5DC/C0>0.019 would justify further testing for glutaric acidemia type I (GA1). The cut-offs were satisfactorily validated via the comparison with worldwide estimates and data for several Caucasian populations. Conclusions The levels of the OA biomarkers in the Serbian population of healthy newborns have a distribution pattern similar to the other world populations. Therefore, the proposed cut-offs represent a reliable starting point for the future development of the OA NBS.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"36 1","pages":"271 - 275"},"PeriodicalIF":0.0,"publicationDate":"2022-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85417081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vitro metabolic biomodulation of irinotecan to increase potency and reduce dose-limiting toxicity by inhibition of SN-38 glucuronide formation","authors":"Rachel A. Crane, Emery S. Grubb, L. Coward, G. Gorman","doi":"10.1515/dmpt-2021-0178","DOIUrl":"https://doi.org/10.1515/dmpt-2021-0178","url":null,"abstract":"Abstract Objectives Colorectal cancer continues to have one of the highest incidents of occurrence with a rising rate of diagnosis among people under the age of 50. Chemotherapy with irinotecan results in severe gastrointestinal dose-limiting toxicity that is caused by the glucuronidated form of the active metabolite (SN-38G). This study evaluates herbal compounds and analogs to biomodulate the metabolism of IR to decrease dose-limiting toxicity while increasing the amount of the active metabolite. Methods In vitro metabolism using human liver microsomes was conducted with white willow bark (WWB) extract, select specific components of WWB, and analogues to evaluate biomodulation of the IR metabolism. Samples were analyzed using liquid chromatography-tandem mass spectrometry to measure metabolites between reactions with and without herbals components. Results WWB showed an optimal decrease (>80%) in SN-38G and a corresponding increase in SN-38 levels (128%) at a concentration of near 200 μg/mL. Tannic acid produced a 75% decrease in SN-38G with a 130% increase in SN-38 at 10 μg/mL, whereas the treatment with beta-pentagalloyl glucose and various analogues decreased SN-38G by 70% and increased SN-38 by 20% at 10 μg/mL. Conclusions These results suggest naturally occurring compounds from WWB may have the potential to increase potency by increasing the conversion of IR to SN-38 and decrease dose-limiting toxicity of IR chemotherapy by reducing glucuronidation of SN-38.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"133 1","pages":"295 - 303"},"PeriodicalIF":0.0,"publicationDate":"2022-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76954374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frontmatter","authors":"","doi":"10.1515/dmpt-2022-frontmatter1","DOIUrl":"https://doi.org/10.1515/dmpt-2022-frontmatter1","url":null,"abstract":"","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80541273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}